ATE553185T1 - Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle - Google Patents

Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle

Info

Publication number
ATE553185T1
ATE553185T1 AT04711259T AT04711259T ATE553185T1 AT E553185 T1 ATE553185 T1 AT E553185T1 AT 04711259 T AT04711259 T AT 04711259T AT 04711259 T AT04711259 T AT 04711259T AT E553185 T1 ATE553185 T1 AT E553185T1
Authority
AT
Austria
Prior art keywords
expression
vector
exogeneous
transient
molecules
Prior art date
Application number
AT04711259T
Other languages
German (de)
English (en)
Inventor
William Sisk
Holly Prentice
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE553185T1 publication Critical patent/ATE553185T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Tents Or Canopies (AREA)
  • Paints Or Removers (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AT04711259T 2003-02-14 2004-02-13 Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle ATE553185T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44817903P 2003-02-14 2003-02-14
PCT/US2004/004407 WO2004074439A2 (en) 2003-02-14 2004-02-13 An expression cassette and vector for transient or stable expression of exogenous molecules

Publications (1)

Publication Number Publication Date
ATE553185T1 true ATE553185T1 (de) 2012-04-15

Family

ID=32908549

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04711259T ATE553185T1 (de) 2003-02-14 2004-02-13 Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle

Country Status (21)

Country Link
US (2) US7494805B2 (enExample)
EP (1) EP1594955B1 (enExample)
JP (2) JP2006517802A (enExample)
KR (1) KR20050101554A (enExample)
CN (1) CN1774500B (enExample)
AT (1) ATE553185T1 (enExample)
AU (1) AU2004213797B2 (enExample)
BR (1) BRPI0407487A (enExample)
CA (1) CA2515481A1 (enExample)
DK (1) DK1594955T3 (enExample)
EA (2) EA200700469A1 (enExample)
ES (1) ES2384973T3 (enExample)
IL (1) IL170178A (enExample)
IS (1) IS7974A (enExample)
MX (1) MXPA05008523A (enExample)
NO (1) NO20054202L (enExample)
NZ (1) NZ542316A (enExample)
PL (1) PL378110A1 (enExample)
RS (1) RS20050614A (enExample)
WO (1) WO2004074439A2 (enExample)
ZA (1) ZA200506413B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700469A1 (ru) * 2003-02-14 2008-10-30 Байоджен Айдек Ма Инк. Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул
ATE542793T1 (de) 2003-09-19 2012-02-15 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
RS20060266A (sr) * 2003-10-14 2008-09-29 Biogen Idec Ma Inc., Flp posredovana rekombinacija
BRPI0508862A (pt) * 2004-03-15 2007-09-04 Biogen Idec Inc métodos e construtos para expressar multìmeros de polipeptìdios em células eucarióticas utilizando junção alternativa
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
UY30288A1 (es) 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
US20080166766A1 (en) * 2006-10-18 2008-07-10 The Scripps Research Institute Genetic incorporation of unnatural amino acids into proteins in mammalian cells
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
WO2011084659A1 (en) * 2009-12-21 2011-07-14 Sanofi-Aventis Transgenic non-human animal and uses thereof
UY33126A (es) * 2009-12-21 2011-07-29 Sanofi Sa Animal transgénico no humano y sus usos
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9816102B2 (en) 2012-09-13 2017-11-14 Indiana University Research And Technology Corporation Compositions and systems for conferring disease resistance in plants and methods of use thereof
ES2780398T3 (es) 2012-12-10 2020-08-25 Biogen Ma Inc Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos
WO2014162318A2 (en) * 2013-03-30 2014-10-09 Usha Biotech Limited Methods and constructs for expressing biologically active proteins in mammalian cells
WO2015162930A1 (ja) * 2014-04-24 2015-10-29 一般社団法人 医療産業イノベーション機構 タンパク質発現を向上させる方法およびタンパク質発現用組成物
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US11415263B2 (en) * 2020-03-20 2022-08-16 Edwards Vacuum Llc Conversion kit for a support frame, a support frame and an integrated vacuum system mounted in a support frame

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA2121798C (en) 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
ATE229076T1 (de) 1992-04-02 2002-12-15 Sembiosys Genetics Inc Cis elemente des ölkörperproteins als regulationische signale
CA2223103A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
CA2222914C (en) 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
WO1997040165A1 (en) * 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
EP1047774A1 (en) * 1998-01-16 2000-11-02 California Pacific Medical Center Research Institute Methods and compositions for gene delivery
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
ES2326893T3 (es) * 1998-05-27 2009-10-21 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
EP1092768A1 (en) * 1999-10-16 2001-04-18 ARTEMIS Pharmaceuticals GmbH Conditional gene trapping construct for the disruption of genes
WO2001094599A1 (en) 2000-06-07 2001-12-13 Smittskyddsinstitutet Gene expression cassette and its use
WO2002002765A2 (en) 2000-07-05 2002-01-10 Transgene S.A. Chimeric promoters for controlling expression in smooth muscle cells
JP2002233374A (ja) * 2001-02-06 2002-08-20 Japan Science & Technology Corp 遺伝子導入及び/又は遺伝子欠損非ヒト動物作製用ベクター
DE10133407A1 (de) 2001-07-13 2003-01-23 Basf Ag Expressionskassetten zur transgenen Expression von Nukleinsäuren
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
EA200700469A1 (ru) 2003-02-14 2008-10-30 Байоджен Айдек Ма Инк. Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул

Also Published As

Publication number Publication date
PL378110A1 (pl) 2006-03-06
CN1774500B (zh) 2011-03-02
JP2010213718A (ja) 2010-09-30
WO2004074439A9 (en) 2004-12-23
AU2004213797B2 (en) 2009-09-17
US20100158879A1 (en) 2010-06-24
KR20050101554A (ko) 2005-10-24
US20060141625A1 (en) 2006-06-29
DK1594955T3 (da) 2012-06-25
RS20050614A (sr) 2007-12-31
AU2004213797A1 (en) 2004-09-02
ES2384973T3 (es) 2012-07-16
HK1084690A1 (en) 2006-08-04
IS7974A (is) 2005-08-11
IL170178A (en) 2011-12-29
MXPA05008523A (es) 2005-10-20
CN1774500A (zh) 2006-05-17
EP1594955B1 (en) 2012-04-11
US7494805B2 (en) 2009-02-24
WO2004074439A2 (en) 2004-09-02
CA2515481A1 (en) 2004-09-02
EA008439B1 (ru) 2007-06-29
EA200501296A1 (ru) 2006-04-28
WO2004074439A3 (en) 2004-10-28
BRPI0407487A (pt) 2006-02-14
ZA200506413B (en) 2006-04-26
EA200700469A1 (ru) 2008-10-30
NO20054202L (no) 2005-11-11
EP1594955A2 (en) 2005-11-16
NO20054202D0 (no) 2005-09-09
JP2006517802A (ja) 2006-08-03
EP1594955A4 (en) 2006-07-19
NZ542316A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
ATE553185T1 (de) Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
DK1601776T3 (da) Ekspressionsvektorer omfattende mCmV-IE2-promotoren
NO20080373L (no) Utvidbarhet av brukergrensesnitt pa grunnlag av oppkoding
GB2445482A (en) Searching data storage systems and devices
ATE424159T1 (de) Katheter
WO2007126883A3 (en) Surveying sterilizer methods and systems
ATE479181T1 (de) Fahrzeuginformations-displays
DE502004004659D1 (de) Verwendung von diphenylmethan-derivaten als tyrosinase-inhibitoren
DE60239831D1 (de) Auf trans-splicing basierende amplifikationsvectoren
DE50307886D1 (de) Leitungsführungseinheit zur aktiven führung von leitungen, kabeln oder dergleichen
WO2008073629A3 (en) Bifunctional predictors of cancer treatment sensitivity and resistance
WO2007025247A3 (en) Transglutaminase inhibitors and methods of use thereof
MY144672A (en) Inhibitors of cytosolic phospholipase a2
WO2005051974A3 (en) Novel molecules for regulating cell death
DE50306741D1 (de) Tragband sowie leitungsführungsanordnung zur stationären führung von leitungen, kabeln od. dgl.
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
AU2003294253A1 (en) Emulsions including surface-modified organic molecules
WO2007050795A3 (en) Transglutaminase inhibitors and methods of use thereof
ATE404602T1 (de) Wässrige polyurethanzubereitungen
EP1695069A4 (en) HYDROGEN SULFIDE MONITORING SYSTEM
NO20082852L (no) Faramsoytisk blanding samt bruk av alfa-hydroksy karbonylforbindelser som reduksjonsmidler
WO2004104030A3 (fr) Peptides modulateurs de l'activite du facteur de transcription engrailed
WO2003091447A3 (en) D1-1 nucleic acids, polypeptides and related methods
ATE470179T1 (de) Bearbeitung von aufmass- und teileversatzsteuerung